03 August 2018
Visiongain has launched a new pharma report Botanical and Plant-Derived Drugs Market Report : Prospects for Leading Companies in Steroids, Phenols, Terpenes, Glycosides and Others, Sativex, Marinol Nabilone, Dexanabinol, CT-3, Cannabinor, HU 308, HU 331, Rimonabant, Taranabant
Plant derived substances have recently become of great interest owing to their versatile applications. Medicinal plants have been used for centuries as remedies for human diseases and offer a new source of biologically active chemical compound as antimicrobial agent. Medicinal plants are the richest bio-resources of drugs of traditional medicinal systems, modern medicines, nutraceuticals, food supplements, folk medicines, pharmaceuticals, intermediate and chemical entitled for synthetic drugs. It has been estimated that 14 - 28% of higher plant species are used medicinally and that 74% of pharmacologically active plant derived components were discovered after following up on ethno medicinal use of the plants. Botanical drugs are those drugs which are derived from medicinal plants. Plant derived drugs are combination of botanical as well as other approved drugs that contains plant materials, synthetic and semi synthetic substances.
The lead analyst of the report commented “There has been rising interest in botanical drugs, with many pharmaceutical companies investigating the commercial potential. The global botanical derived drugs market will experience steady growth over the forecast period.
Growth in the market is primarily driven by increasing focus on the development of drugs for new indications, increasing prevalence of various chronic diseases and public as well as private investment for botanical and plant derived drug. However, challenges in clinical trials and stringent laws and regulations for approval will deplete the market.”
Leading companies featured in the report include Abbott Laboratories, Bayer AG, Eli Lilly
Johnson & Johnson, Novartis AG, Pfizer, Inc., Bristol-Myers Squibb (BMS), Medigene AG
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.
26 November 2020
Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.
26 November 2020
Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.
25 November 2020
Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth